- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01667302
Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma
March 2, 2013 updated by: Ye Guo, Fudan University
A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
For patients with stage I/II NK/T-cell lymphoma, the sequence of radiotherapy and chemotherapy is controversial.
Some studies demonstrated the advantage of upfront radiotherapy.
Therefore, we designed this single-arm phase II study to evaluate the efficacy and safety of radiotherapy followed by adjuvant chemotherapy with DICE regimen plus peg-asparaginase which was proved to be effective in NK/T-cell lymphoma.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
SHanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age range 14-70 years old
- Histological confirmed, previously untreated stage I/II NK/T cell lymphoma in the upper-aerodigestive tract
- ECOG performance status 0-1
- Life expectancy of more than 3 months
- Without prior history of pancreatitis
- Adequate bone marrow and organ functions
Exclusion Criteria:
- Low risk population (Definition: stage I without local invasion, B symptoms and high LDH level)
- Pregnant or lactating women
- With contraindication of steroid including uncontrolled diabetes
- Serious uncontrolled diseases and intercurrent infection
- History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Radiotherapy followed by chemotherapy
Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
|
Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
3-year Progression-free survival
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
3-year overall survival
Time Frame: 3 years
|
3 years
|
Overall response rate
Time Frame: 3 years
|
3 years
|
Safety
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (ANTICIPATED)
December 1, 2013
Study Completion (ANTICIPATED)
December 1, 2016
Study Registration Dates
First Submitted
August 13, 2012
First Submitted That Met QC Criteria
August 15, 2012
First Posted (ESTIMATE)
August 17, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
March 5, 2013
Last Update Submitted That Met QC Criteria
March 2, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LMTG 12-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extranodal NK/T-cell Lymphoma, Nasal Type
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Ruijin HospitalUnknownNasal Type Extranodal NK/T-Cell LymphomaChina
-
Sun Yat-sen UniversityEli Lilly and Company; Hoffmann-La RocheUnknownExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Fudan UniversityTerminatedExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Jiangsu HengRui Medicine Co., Ltd.UnknownExtranodal NK/T-cell Lymphoma, Nasal TypeChina
-
Ruijin HospitalCompletedNasal Type Extranodal NK/T-Cell LymphomaChina
-
Samsung Medical CenterConsortium for Improving Survival of Lymphoma; Lymphoma Study Association; Deok-Hwan... and other collaboratorsCompletedExtranodal NK/T-cell Lymphoma, Nasal TypeKorea, Republic of
-
Samsung Medical CenterAsan Medical Center; Yonsei University; Seoul National University; Chonnam National...CompletedExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-TypeKorea, Republic of
-
Sun Yat-sen UniversityNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal TypeChina
Clinical Trials on Radiotherapy followed by chemotherapy
-
Cancer Institute and Hospital, Chinese Academy...Shanxi Province Cancer Hospital; 307 Hospital of PLA; Qilu Hospital of Shandong... and other collaboratorsUnknownExtranodal Natural Killer/T-Cell Lymphoma, Nasal TypeChina
-
Eye & ENT Hospital of Fudan UniversityPeking University Third Hospital; Zhongshan Ophthalmic Center, Sun Yat-sen... and other collaboratorsRecruitingMalignant Tumor of Lacrimal Drainage StructureChina
-
Shanghai Jiao Tong University School of MedicineCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage III Oral Cavity Squamous Cell CarcinomaChina
-
Peking Union Medical College HospitalUnknown
-
Peking Union Medical College HospitalUnknown
-
European Institute of OncologyAssociazione Italiana per la Ricerca sul CancroRecruitingAdenocarcinoma of ProstateItaly
-
University Hospital, LilleNational Cancer Institute, FranceRecruitingGastric AdenocarcinomaFrance
-
Tianjin Medical University Cancer Institute and...Tianjin Medical University General Hospital; Tianjin Medical University Second...Not yet recruitingHypopharyngeal CarcinomaChina
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Effects of Chemotherapy | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina